Evidence map›Paper›PMID 42637975›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Diagnostic value of surveillance

Sang Hyun Hwang, Jin Chul Paeng, Arthur Cho, Shin Young Jeong, So Won Oh, Jung Mi Park, Ji Sun Park, Joon Young Choi, Won Jun Kang

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sang Hyun Hwang *Department of Nuclear Medicine, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
Jin Chul Paeng *Department of Nuclear Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Arthur ChoDepartment of Nuclear Medicine, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
Shin Young JeongDepartment of Nuclear Medicine, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
So Won OhDepartment of Nuclear Medicine, Seoul National University Boramae Medical Center, Seoul, Republic of Korea.
Jung Mi ParkDepartment of Nuclear Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Republic of Korea.
Ji Sun ParkDepartment of Nuclear Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea.
Joon Young ChoiDepartment of Nuclear Medicine and Molecular Imaging, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea. gyrus@skku.edu.ORCID http://orcid.org/0000-0003-1060-0096
Won Jun KangDepartment of Nuclear Medicine, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea. MDKWJ@yuhs.ac.ORCID http://orcid.org/0000-0002-2107-8160

Funding

Korean Society of Nuclear Medicine KSNM-CTN-2020-01-1
6 · The paper itself

Abstract

purposeEarly detection of non-small cell lung cancer (NSCLC) recurrence after curative resection is critical for improving survival rates. Although

methodsA total of 6,789 consecutive

resultsDiagnostic sensitivity and specificity of ¹⁸F-FDG PET/CT for detecting NSCLC recurrence were 89.1% (496/557) and 98.4% (6,133/6,232), respectively. Overall diagnostic performance remained consistent regardless of initial stage, histology, or time between operation and scan. Specifically, the positive predictive value for detecting recurrence was significantly higher for scans performed within 12 months than for those performed between 12 and 36 months, whereas the negative predictive value was significantly higher for scans performed after 12 months. Additionally, overall accuracy was higher for stage I than stage II disease.

conclusionsSurveillance

Indexed as

18F-fluorodeoxyglucoseLung cancerNuclear medicinePositron emission tomographySurveillance

Identifiers

PMID42637975

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.